설정
KCSG 소식
- HOME
- 알림
- KCSG 소식
| 주요 연구성과 | 간행물 |
| 미디어 | 연구회 동정 |
| KCSG 인사이트 | 뉴스레터 |
2026 ASCO Annual Meeting에 채택된 KCSG 연구 결과
관리자
2026-06-16
156
2026 ASCO* Annual Meeting에서 KCSG에서 공동으로 수행한 연구결과가 채택되어 발표되었습니다. ASCO에서 빛난 KCSG의 연구 성과에 축하와 박수를 보냅니다! * ASCO: 미국임상암학회 (American Society of Clinical Oncology)
※ 연구번호를 클릭하면 초록을 확인할 수 있습니다.
- KCSG HB23-05: A phase Ib/II trial of First-line Trastuzumab, Nivolumab, Gemcitabine and Cisplatin in HER2-positive biliary tract cancer (HERBOT): a multi-institutional study of the Korean Cancer Study Group
- KCSG LY22-07: Phase II study of tislelizumab plus pemetrexed in patients with relapsed or refractory (R/R) primary diffuse large B-cell lymphoma (DLBCL) of the central nervous system (CNS): the Korean Cancer Study Group LY22-07
- KCSG PC22-11: Comparison of prophylactic effects for Chemotherapy Induced neutropenia between same-day versus next-day administration of pegteograstim in chemotherapy regimen composed of day 1 intensive myleosuppressive agent: A randomized clinical trial (CONCISE, KCSG PC22-11)
- KCSG CO21-21: Efficacy and circulating protein biomarkers of second-line aflibercept plus FOLFIRI according to prior bevacizumab or cetuximab treatment in advanced colorectal cancer (KCSG CO21-21)
- KCSG CO24-03: The role of adjuvant chemotherapy in high-risk stage II colon cancer with microsatellite instability-high or DNA mismatch repair deficiencies: A multicenter pooled analysis (KCSG-CO24-03)
- KCSG CO22-12: Clinicopathological Characteristics of Patients with Minimal Residual Disease in Stage II?III Colon Cancer: Interim Results from the Observational Cohort of CLAUDIA Study
- KCSG CO19-18: Bevacizumab-based triplet versus doublet chemotherapy as first-line treatment for metastatic right-sided colon cancer: Results of the KCSG CO19-18 phase II trial
갤러리 안내
